Company news

Niagen Bioscience, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®

April 24, 2024

ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

April 23, 2024

ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market

April 22, 2024

ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program

March 25, 2024

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

February 20, 2024

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024

February 4, 2024

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

January 25, 2024

ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®

December 19, 2023

Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+

December 11, 2023

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

November 29, 2023

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

November 14, 2023

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023

November 8, 2023

ChromaDex Corporation Reports Third Quarter 2023 Financial Results

November 7, 2023

ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide

October 31, 2023

ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

October 30, 2023

ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line

October 25, 2023

A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients

October 1, 2023

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN

August 23, 2023

ChromaDex Corporation Reports Second Quarter 2023 Financial Results

August 8, 2023

ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness

August 7, 2023

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series

August 6, 2023

ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

August 1, 2023

Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

July 17, 2023

ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging

June 15, 2023

ChromaDex to Participate in the LD Micro Invitational XIII

May 29, 2023

ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference

May 10, 2023

ChromaDex Corporation Reports First Quarter 2023 Financial Results

May 9, 2023

ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

May 1, 2023

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results

March 7, 2023

ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023

March 5, 2023

ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023

February 26, 2023

ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space

February 21, 2023

A Letter from the ChromaDex Chief Executive Officer

February 20, 2023

ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)

January 11, 2023

ChromaDex Named Brianna Gerber Chief Financial Officer

January 4, 2023

ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States

November 10, 2022

ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022

October 25, 2022

ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards

October 23, 2022

ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment

October 10, 2022

ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock

October 2, 2022

Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)

September 18, 2022

ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil

August 31, 2022

Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College

August 14, 2022

ChromaDex Corporation Reports Second Quarter 2022 Financial Results

August 9, 2022

ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)

July 6, 2022

ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)

June 14, 2022

ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China

June 9, 2022

ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference

June 6, 2022

ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea

June 1, 2022

ChromaDex to Present at the LD Micro Invitational

May 31, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 31 calls. Every call is listed under its year.

Decks

The 5 newest of 60 decks. Every deck is listed under its year.